$CLOV

Clover Health former officer plans 141,418-share sale

Clover Health's former officer, Brady Priest, plans to sell 141,418 shares, valued at $631,162.68, according to a regulatory filing. Priest also reported four prior sales totaling 1,205,209 shares between August 7 and September 15, 2026, with proceeds ranging from $305,113.45 to $2,171,597.33.

Original reporting
Published Sep 24, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The disclosed sale provides new information on insider activity, which could influence short-term trading decisions.

02

Market read

Insider sales are a standard data point for traders; this filing adds fresh detail for CLOV.

03

Timing

recent filing

Relevance 5/10Novelty 5/10Timing: recent filing

Background

The article reports a Form 4 insider sale by a former officer of Clover Health, detailing share amounts and proceeds.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

SEC Form 4 filing shows former officer Brady Priest selling 141,418 shares of Clover Health, valued at $631,162.68.

Expected impact

Potential modest dip in share price over the next few days.

Evidence & confidence

Insider sales often signal negative sentiment; the transaction size is modest but notable for a recent filing.

Key entities

  • Clover Health

    US-listed health insurance technology firm (ticker CLOV).

  • Brady Priest

    Former officer of Clover Health executing the share sale.

Related articles

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.